SEARCH

SEARCH BY CITATION

References

  • Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5, 417421.
  • Adams, S., Miller, G.T., Jesson, M.I., Watanabe, T., Jones, B. & Wallner, B.P. (2004) PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Research, 64, 54715480.
  • Anderson, J.R., Armitage, J.O. & Weisenburger, D.D. (1998) Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 9, 717720.
  • Apostolidis, J., Gupta, R.K., Grenzelias, D., Johnson, P.W., Pappa, V.I., Summers, K.E., Salam, A., Adams, K., Norton, A.J., Amess, J.A., Matthews, J., Bradburn, M., Lister, T.A., & Rohatiner, A.Z. (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. Journal of Clinical Oncology, 18, 527536.
  • Ardeshna, K.M., Smith, P., Norton, A., Hancock, B.W., Hoskin, P.J., MacLennan, K.A., Marcus, R.E., Jelliffe, A., Hudson, V.G. & Linch, D.C. British National Lymphoma Investigation. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet, 362, 516522.
  • Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L. & Kwak, L.W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 11711177.
  • Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. & Shen, D. (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 9951001.
  • Van Besien, K., Loberiza, Jr, F.R. Bajorunaite, R., Armitage, J.O., Bashey, A., Burns, L.J., Freytes, C.O., Gibson, J., Horowitz, M.M., Inwards, D.J., Marks, D.I., Martino, R., Maziarz, R.T., Molina, A., Pavlovsky, S., Pecora, A.L., Schouten, H.C., Shea, T.C., Lazarus, H.M., Rizzo, J.D. & Vose, J.M. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102, 35213529.
  • Besson, H., Brennan, P., Becker, N., Nieters, A., De Sanjose, S., Font, R., Maynadie, M., Foretova, L., Cocco, P.L., Staines, A., Vornanen, M. & Boffetta, P. (2006) Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: a European multicenter case-control study (Epilymph). International Journal of Cancer, 119, 901908.
  • Bierman, P.J., Vose, J.M., Anderson, J.R., Bishop, M.R., Kessinger, A. & Armitage, J.O. (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 15, 445450.
  • Buske, C., Hoster, E., Dreyling, M., Hasford, J., Unterhalt, M & Hiddemann, W. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome. Blood, 108, 15041508.
  • Chiu, B.C. & Weisenburger, D.D. (2003) An update of the epidemiology of non-Hodgkin's lymphoma. Clinical Lymphoma, 4, 161168.
  • Chiu, B.C., Dave, B.J., Blair, A., Gapstur, S.M., Zahm, S.H. & Weisenburger, D.D. (2006) Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood, 108, 13631369.
  • Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. & Solal-Celigny, P. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 97, 101106.
  • Czuczman, M.S., Weaver, R., Alkuzweny, B., Berlfein, J. & Grillo-Lopez, A.J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular Non-Hodgkin's lymphoma treated with Rituximab plus CHOP chemotherapy: 9 year follow-up. Journal of Clinical Oncology, 22, 46594664.
  • Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P., Cornillet-LeFebvre, P., Escoffre-Barbe, M., Maisonneuve, H., Delwail, V., Gressin, R., Legouffe, E., Vilque, J.P., Desablens, B., Jaubert, J., Ramee, J.F., Jenabian, A., Thyss, A., Le Pourhiet-Le Mevel, A., Travade, P., Delepine, R. & Colombat, P. (2005) High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS. Blood, 105, 38173823.
  • Emmanouilides, C., Witzig, T.E., Gordon, L.I., Vo, K., Wiseman, G.A., Flinn, I.W., Darif, M., Schilder, R.J. & Molina, A. (2006) Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leukemia Lymphoma, 47, 629636.
  • Feuring-Buske, M., Kneba, M., Unterhalt, M., Engert, A., Gramatzki, M., Hiller, E., Trumper, L., Brugger, W., Ostermann, H., Atzpodien, J., Hallek, M., Aulitzky, E. & Hiddemann, W. (2000) IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Annals of Hematology, 79, 493500.
  • Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 84478452.
  • Forrest, D.L., Thompson, K., Nevill, T.J., Couban, S. & Fernandez, L.A. (2002) Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplantation, 29, 973978.
  • Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Bock, H.P., Wandt, H., Unterhalt, M. & Hiddemann, W. German Low-Grade Lymphoma Study Group. (2004) The addition of Rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantel cell Lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 104, 30643071.
  • Freedman, A.S., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. & Gribben, J.G. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, 33253333.
  • Friedberg, J.W., Kelly, J., Kutok, J.L., Salloum, R., Brenn, T., Fisher, D., Ronan, E., McCauley, M., Rich, L., Marquis, D., Rothberg, P.G., Liesveld, J., Fisher, R., Coffmann, R., Mosmann, T. & Freedman, A. (2005) CpG Oligonucleotide (1018 ISS) may overcome Rituximab (R) resistance in follicular lymphoma (FL) through enhanced ADCC, T cell expansion, and alteration of tumor microenvironment. Blood, 106, 684a.
  • Gallagher, C.J., Gregory, W.M., Jones, A.E., Stansfeld, A.G., Richards, M.A., Dhaliwal, H.S., Malpas, J.S. & Lister, T.A. (1986) Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology, 4, 14701480.
  • Gascoyne, R.D., Krajewska, M., Krajewski, S., Connors, J.M. & Reed, J.C. (1997) Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90, 31733178.
  • Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103, 44164423.
  • Gopal, A.K., Gooley, T.A., Maloney, D.G., Petersdorf, S.H., Eary, J.F., Rajendran, J.G., Bush, S.A., Durack, L.D., Golden, J., Martin, P.J., Matthews, D.C., Appelbaum, F.R., Bernstein, I.D. & Press, O.W. (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood, 102, 23512357. Epub 2003 May 2315.
  • Gordan, L., Grow, W.B., Pusateri, A., Douglas, V., Mendenhall, N.P. & Lynch, J.W. (2005) A phase II trial of individualized pharmacokinetic dosing of rituximab maintenance for patients with CD-20 positive lymphoproliferative disorders. Journal of Clinical Oncology, 23, 10961102.
  • Groves, F.D., Linet, M.S., Travis, L.B. & Devesa, S.S. (2000) Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. Journal of the National Cancer Institute, 92, 12401251.
  • Grulich, A.E. & Vajdic, C.M. (2005) The epidemiology of non-Hodgkin lymphoma. Pathology, 37, 409419.
  • Guadagnolo, B.A., Li, S., Neuberg, D., Ng, A., Hua, L., Silver, B., Stevenson, M.A. & Mauch, P. (2006) Long-term outcome andmortality trends in early stage, grade 1–2 follicular lymphoma treated with radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 64, 928934.
  • Hainsworth, J.D., Litchy, S., Burris, III H.A., Scullin, Jr, D.C., Corso, S.W., Yardley, D.A., Morrissey, L. & Greco, F.A. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 42614267.
  • Hainsworth, J.D., Litchy, S., Shaffer, D.W., Lackey, V.L., Grimaldi, M. & Greco, F.A. (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomised phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 23, 10881095.
  • Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 38353849.
  • Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D., Neubauer, A., Dölken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Hoeffken, K., Franke, A., Ittel, T.H., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., Von Grünhagen, U., Dachselt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F.A., Lakner, V., Richter, P., Hähling, D., Wolf, H.H., Eschenburg, H., Clemens, M.R. & Grobe, N. (2004) Results of a prospective randomised open label phase III study comparing Rituximab plus Mitoxantrone, Chlorambucil, Prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood, 104, 584a.
  • Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005a) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 37253732.
  • Hiddemann, W., Forstpointner, R., Dreyling, M., Gramatzki, M., Böck, H.P., Haenel, M., Seymour, J.F. & Unterhalt, M. (2005b) Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proceedings of the American Social and Clinical Oncology, 23, 566.
  • Hochster, H.S., Weller, E., Ryan, T., Habermann, T.M., Gascoyne, R., Frankel, R.S. & Horning, S.J. (2004) Results of E 1496: a phase III trial of CVP with or without maintenance Rituximab in advanced indolent lymphoma (NHL). Proceedings of the American Social and Clinical Oncology, 23, 556.
  • Hochster, H.S., Weller, E., Gascoyne, R.D., Ryan, T.S., Habermann, T.M., Gordon, L.I., Frankel, S.R. & Hornig, S.J. (2005) Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood, 106, 106a. (Abstract 349).
  • Horning, S.J. & Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine, 311, 14711475.
  • Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G. & Wahl, R.L. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96, 12591266.
  • Kaminski, M.S., Zelenetz, A.D., Press, O.W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T.A., Stagg, R.J., Tidmarsh, G.F., Kroll, S., Wahl, R.L., Knox, S.J. & Vose, J.M. (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 19, 39183928.
  • Kaminski, M.S., Tuck, M., Estes, J., Kolstad, A., Ross, C.W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S. & Wahl, R.L. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. New England Journal of Medicine, 352, 441449.
  • Khouri, I.F., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, P., Anderlini, P., Donato, M.L., Cabanillas, F.F. & Champlin, R.E. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 98, 35953599.
  • Lennert, K., Stein, H. & Kaiserling, E. (1975) Cytological and functional criteria for the classification of malignant lymphomata. British Journal of Cancer, 31 (Suppl. 2), 2943.
  • Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H., Freund, M., Hess, G., Truemper, L., Diehl, V., Kropff, M., Kneba, M., Schmitz, N., Metzner, B., Pfirrmann, M., Unterhalt, M. & Hiddemann, W. (2004a) German Low-Grade Lymphoma Study Group. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood, 104, 26672674.
  • Lenz, G., Dreyling, M., Schiegnitz, E., Haferlach, T., Hasford, J., Unterhalt, M. & Hiddemann, W. (2004b) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Journal of Clinical Oncology, 22, 49264933.
  • Leonard, J.P., Coleman, M., Kostakoglu, L., Chadburn, A., Cesarman, E., Furman, R.R., Schuster, M.W., Niesvizky, R., Muss, D., Fiore, J., Kroll, S., Tidmarsh, G., Vallabhajosula, S. & Goldsmith, S.J. (2005) Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of Clinical Oncology, 23, 56965704.
  • Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F.B., Ayers, G.D., Hess, M., Romaguera, J., Rodriguez, M.A., Tsimberidou, A.M., Verstovsek, S., Younes, A., Pro, B., Lee, M.S., Ayala, A. & McLaughlin, P. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology, 24, 15821589.
  • Mac Manus, M.P. & Hoppe, R.T. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology, 14, 12821290.
  • Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 21882195.
  • Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 14171423.
  • McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Morschhauser, F., Leonard, J., Coiffier, B., Petillon, M., Coleman, M., Bahkti, A., Sapra, P., Teoh, N., Wegener, W.A., Horak, I.D. & Goldenberg, D.M. (2005) Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma. Blood, 106, 683a.
  • Morton, L.M., Hartge, P., Holford, T.R., Holly, E.A., Chiu, B.C., Vineis, P., Stagnaro, E., Willett, E.V., Franceschi, S., La Vecchia, C., Hughes, A.M., Cozen, W., Davis, S., Severson, R.K., Bernstein, L., Mayne, S.T., Dee, F.R., Cerhan, J.R. & Zheng, T. (2005) Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiology, Biomarkers and Prevention, 14, 925933.
  • Murtha, A.D., Rupnow, B.A., Hanson, J., Knox, S.J. & Hoppe, R. (2001) Long-term follow-up of patients with stage III follicular lymphoma treated with primary radiotherapy at Stanford University. International Journal of Radiation Oncology, Biology, Physics, 49, 315.
  • Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D., Dagis, A., Kwok, C., Yamauchi, D., Anderson, A.L., Falk, P., Krishnan, A., Kirschbaum, M., Kogut, N., Nakamura, R., O'Donnell, M., Parker, P., Popplewell, L., Pullarkat, V., Rodriguez, R., Sahebi, F., Smith, E., Snyder, D., Stein, A., Spielberger, R., Zain, J., White, C. & Raubitschek, A. (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood, 106, 28962902.
  • Niitsu, N., Hayama, M., Okamoto, M., Khori, M., Higashihara, M., Tamaru, J. & Hirano, M. (2004) Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clinical Cancer Research, 10, 40774082.
  • O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676684.
  • Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 44204427.
  • Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., Deventer, H.W.V., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D., Trehu, E., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. & Dees, E.C. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 30583065.
  • Ott, G., Katzenberger, T., Lohr, A., Kindelberger, S., Rudiger, T., Wilhelm, M., Kalla, J., Rosenwald, A., Muller, J.G., Ott, M.M. & Muller-Hermelink, H.K. (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood, 99, 38063812.
  • Ott, O.J., Rodel, C., Gramatzki, M., Niedobitek, G., Sauer, R. & Grabenbauer, G.G. (2003) Radiotherapy for stage I-III nodal low-grade non- Hodgkin's lymphoma. Strahlentherapie und Onkologie, 179, 694701.
  • Pendlebury, S., El Awadi, M., Ashley, S., Brada, M. & Horwich, A. (1995) Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiotherapy and Oncology, 36, 167171.
  • Peniket, A.J., Ruiz de Elvira, M.C., Taghipour, G., Cordonnier, C., Gluckman, E., De Witte, T., Santini, G., Blaise, D., Greinix, H., Ferrant, A., Cornelissen, J., Schmitz, N., Goldstone, A.H. & European Bone Marrow Transplantation (EMBT) Lymphoma Registry (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation, 31, 667678.
  • Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Badger, C.C., Nelp, W.B., Glenn, S., Butchko, G., Fisher, D. & Porter, B. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New England Journal of Medicine, 329, 12191224.
  • Press, O.W., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., LeBlanc, M., Gaynor, E.R., Rivkin, S.E. & Fisher, R.I. (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood, 102, 16061612. Epub 2003 May 1608.
  • Ramanarayanan, J., Hernandez-Ilizaliturri, F.J. & Czuczman, M.S. (2004) In vivo downregulation of Bcl-2 by G3139 (G) enhances rituximab (R) anti-tumor activity: effect of sequential versus concurrent G3139 Administration on survival in a lymphoma-bearing SCID Mouse Model. Blood, 104, 392a.
  • Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435445.
  • Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., Ruiz de Elvira, C., Taghipour, G. & Schmitz, N. (2002) Chemoresistance or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, 43104316.
  • Salles, G., Foussard, C., Mournier, N., Morschhauser, F., Doyen, C., Lamy, T., Haioun, C., Brice, P., Bouabdallhah, R., Rossi, J.F., Audhuy, B., Freme, C., Mahe, B., Feugier, P., Sebban, C., Colombat, P. & Xerri, L. (2004) Rituximab added to aIFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood, 104, 160a.
  • De Sanjose, S., Benavente, Y., Nieters, A., Foretova, L., Maynadie, M., Cocco, P.L., Staines, A., Vornanen, M., Boffetta, P., Becker, N., Alvaro, T. & Brennan, P. (2006) Association between personal use of hair dyes and lymphoid neoplasms in Europe. American Journal of Epidemiology, 164, 4755.
  • Schouten, H.C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnson, H.E., Doorduijn, J.K., Sydes, M.R. & Kvalheim, G. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology, 21, 39183927.
  • Sebban, C., Belanger, C., Brousse, N., Mournier, N., Brice, P., Haioun, C., Tilly, H., Feugier, P., Bouabdallah, R., Bosly, A. & Coiffier, B. (2003) Comparison of CHVP + Interferon with followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial (G.E.L.A. Study Group). Blood, 102, 354a.
  • Shan, D., Ledbetter, J.A. & Press, O.W. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology, Immunotherapy, 48, 673683.
  • Shipley, D.L., Greco, F.A. & Spigel, D.R. (2005) Rituximab with short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. Proceedings of the American Society of Clinical Oncology, 23, 579s (no. 6577).
  • Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haioun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. & Montserrat, E. (2004) Follicular lymphoma international prognostic index. Blood, 104, 12581265.
  • Stuschke, M., Hoederath, A., Sack, H., Pötter, R., Müller, R.P., Schulz, U., Karstens, J. & Makoski, H.B. (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Cancer, 80, 22732284.
  • Sweetenham, J.W., Dicke, K., Arcaroli, J., Kogel, K., Rana, T.M. & Rice, L.L. (2004) Efficacy and safety of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin) Therapy with Rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood, 104, 720a (no. 2633).
  • Tanimoto, T.E., Kusumi, E., Hamaki, T., Yuji, K., Ueyama, J., Miyakoshi, S., Morinaga, S., Kami, M., Kanda, Y., Ando, T., Yoshihara, S., Masuo, S., Kim, S.W., Nakai, K., Tobinai, K., Tanosaki, R., Mineishi, S., Takaue, Y. & Muto, Y. (2003) High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transplantation, 32, 131137.
  • The Non-Hodgkin's Lymphoma Classification Project. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89, 39093918.
  • The Non-Hodgkin's Lymphoma Pathologic Classification Project. (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer, 15, 49, 21122135.
  • Totze, C.L., Barnett, M.J., Connors, J.M., Gascoyne, R.D., Voss, N.J., Nantel, S.H., Nevill, T.J., Shepherd, J.D., Sutherland, H.J., Lavoie, J.C., Forrest, D.L., Song, K.W. & Hogge, D.E. (2004) Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. British Journal of Haematology, 127, 311321.
  • Van Oers, M.H.J., Van Glabbeke, M., Teodorovic, I., Rozewicz, C., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E. & Hagenbeek, A. (2005) Chimeric anti-CD 20 monoclonal antibody (Rituximab, Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: a phase III randomized intergroup clinical trial. Proceedings of the American Society of Hematology, 104, 169a.
  • De Vos, S., Dakhil, S.R., McLaughlin, P., Saleh, M., Belt, R., Flowers, C., Knapp, M., Hart, S., Patel-Donnelly, D., Glenn, S., Gregory, S.A., Holladay, C., Boral, A., Zhang, T. & Goy, A. (2005) Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study. Blood, 106, 107a.
  • Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, S.J., Radford, J.A., Zelenetz, A.D., Tidmarsh, G.F., Stagg, R.J. & Kaminski, M.S. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 18, 13161323.
  • Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., Di Stefano, F., & Cotter, F.E. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 18, 18121823.
  • Weng, W.K. & Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 39403947.
  • Weng, W.K., Czerwinski, D., Timmerman, J., Hsu, F.J. & Levy, R. (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Journal of Clinical Oncology, 22, 47174724.
  • Wilder, R.B., Jones, D., Tucker, S.L., Fuller, L.M., Ha, C.S., McLaughlin, P., Hess, M.A., Cabanillas, F. & Cox, J.D. (2001) Long-term results with radiotherapy for stage I-II follicular lymphomas. International Journal of Radiation Oncology, Biology, Physics, 51, 12191227.
  • Wiseman, G.A., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S., Bartlett, N.L., Schilder, R.J., Murray, J.L., Saleh, M., Allen, R.S., Grillo-Lopez, A.J. & White, C.A. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 99, 43364342.
  • Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R.J., Spies, S., Silverman, D.H., Parker, E. & Grillo-Lopez, A.J. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 37933803.
  • Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N., Grillo-Lopez, A.J., Multani, P. & White, C.A. (2002a) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 24532463.
  • Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P.S. & White, C.A. (2002b) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 32623269.